High risk strategies for atherosclerosis

Clinica Chimica Acta

Volumn 286, Issue 1-2, 1999, Pages 31-45

  Cullen, Paul ^a   Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Coronary heart disease; Risk assessment; Risk factors

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ALGORITHM; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONFERENCE PAPER; FAMILY HISTORY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

ALGORITHMS; ARTERIOSCLEROSIS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, LDL; MALE; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 0032838333     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(99)00092-3     Document Type: Conference Paper

References (36)

1. Assmann G., Cullen P., Schulte H. The Munster Heart Study (PROCAM) - Results of follow-up at 8 years. Eur Heart J. 19:1998;A2-A11.
2. Assmann G., Schulte H., Cullen P. New and classical risk factors - the Münster Heart Study (PROCAM). Eur J Med Res. 2:1997;237-242.
3. Anderson K.M., Castelli W.P., Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA. 257:1987;2176-2180.
4. Keil U., Liese A.D., Hense H.W., et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Eur Heart J. 19:1998;1197-1207.
5. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. (89):1994;1329-1445.
6. Assmann G., Carmena R., Cullen P., et al. Coronary heart disease: reducing the risk. The scientific background to the primary and secondary prevention of coronary heart disease - a worldwide view. Nutr Metab Cardiovasc Dis. 8:1998;158-217.
7. Neaton J.D., Blackburn H., Jacobs D., et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Int Med. 152:1992;1490-1500.
8. The Lipid Research Clinics Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. (251):1984;351-374.
9. Clin Cardiol. (21):1998;54. (abst ).
10. The Long Term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular disease and death with prevastatin in patients with coronary heart disease and a broad range of initial cholesterol values. N Engl J Med 1998;339:1349-57.
11. Sacks F.M., Pasternak R.C., Gibson C.M., Rosner B., Stone P.H. Effect on coronary atherosclerosis of decrease in plasma-cholesterol concentrations in normocholesterolemic patients. Lancet. 344:1994;1182-1186.
12. Pedersen T.R., Kjekshus J., Berg K., et al. Base line serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 345:1995;1274-1275.
13. Shepherd J., Cobbe S.M., Lorimer A.R., et al. Screening experience and base-line characteristics in the West of Scotland coronary prevention study. Am J Cardiol. 76:1995;485-491.
14. Law M.R., Wald N.J., Thompson S.G. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 308:1994;367-373.
15. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
16. Campeau L., Knatterud G.K., Domanski M., et al. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-162.
17. Assmann G., Schulte H., vonEckardstein A. Hypertriglyceridemia and elevated levels of lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 77:1996;1179-1184.
18. Assmann G., Cullen P., Heinrich J., Schulte H. Hemostatic variables in the prediction of coronary risk - results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Isr J Med Sci. 32:1996;364-370.
19. Grundy S.M., Bilheimer D., Chait A., et al. Summary of the 2nd report of the national-cholesterol-education- program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
20. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol. 81:1998;582-587.
21. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 81:1998;B66-B69.
22. Nawrocki J.W., Weiss S.R., Davidson M.H., et al. Reduction of LDL cholesterol by 25-percent to 60-percent in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
23. Pfeffer M.A., Sacks F.M., Moye L.A., et al. Cholesterol and recurrent events - a secondary prevention trial for normolipidemic patients. Am J Cardiol. 76:1995;98C-106C.
24. Dart A., Jerums G., Nicholson G., et al. A multicenter, double-blind, one-year study comparing safety and efficacy of Atorvastatin versus Simvastatin in patients with hypercholesterolemia. Am J Cardiol. 80:1997;39-44.
25. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. (344):1994;1383-1389.
26. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
27. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.
28. Stein E.A., Davidson M.H., Dujovne C.A., et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia. J Cardiovasc Pharmacol Ther. 1:1996;107-116.
29. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study. Circulation. 97:1998;1453-1460.
30. Frayn K.N. Insulin resistance and lipid metabolism. Curr Op Lipidol. 4:1993;197-204.
31. Assmann G, Cullen P, Jossa F, Lewis B, Mancini M. Coronary heart disease, reducing the risk. The scientific background to the primary and secondary prevention of coronary heart disease, a worldwide view. Arterioscler.Thromb.Vasc.Biol. 1998 (in press).
32. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 317:1987;1237-1245.
33. Shepherd J. The West of Scotland coronary prevention study - a trial of cholesterol reduction in Scottish men. Am J Cardiol. 76:1995;C113-C117.
34. Packard C.J., Shepherd J., Cobbe S.M., et al. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
35. Downs J.R., Beere P.A., Whitney E., et al. Design & rationale of the Air Force Texas coronary atherosclerosis prevention study (AFCAP/TexCAPS). Am J Cardiol. 80:1997;287-293.
36. Whitney E., Clearfield M., Downs J.R., et al. Air Force Texas coronary atherosclerosis prevention study: Design and baseline characteristics. J Am Coll Cardiol. (29):1997;3163. (abst.).